Quality of warfarin-associated INR monitoring and time in INR therapeutic range
| eGFR group | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥120 | 105–119 | 90–104 | 60–89 | 45–59 | 30–44 | 15–29 | <15 | Dialysis | Total | p Value | |
| Mean INR monitoring rate | |||||||||||
| Full cohort | 84.5% (n=147) | 86.5% (n=1193) | 86.4% (n=8198) | 85.8% (n=35 473) | 85.6% (n=14 577) | 85.7% (n=6652) | 86.2% (n=1786) | 85.0% (n=267) | 86.6% (n=334) | 85.8% (n=68 627) | 0.2 |
| Heart failure | 86.3% (n=24) | 84.3% (n=152) | 86.6% (n=966) | 86.6% (n=4768) | 86.4% (n=2801) | 86.2% (n=1844) | 87.0% (n=604) | 86.2% (n=84) | 86.4% (n=153) | 86.5% (n=11 369) | 0.96 |
| No heart failure | 84.2% (n=123) | 86.9% (n=1041) | 86.4% (n=7232) | 85.7% (n=30 705) | 85.4% (n=11 776) | 85.5% (n=4808) | 85.8% (n=1182) | 84.4% (n=183) | 86.8% (n=181) | 85.7% (n=57 231) | 0.06 |
| Age<75 | 84.5% (n=147) | 86.4% (n=1173) | 86.5% (n=7727) | 86.0% (n=21 873) | 86.4% (n=6272) | 86.4% (n=2225) | 86.5% (n=660) | 84.4% (n=150) | 85.5% (n=254) | 86.2% (n=40 481) | 0.67 |
| Age≥75 | 0 | 92.2% (n=20) | 85.7% (n=471) | 85.5% (n=13 600) | 85.0% (n=8305) | 85.4% (n=4427) | 86.0% (n=1126) | 85.7% (n=117) | 90.2% (n=80) | 85.4% (n=28 146) | 0.26 |
| Mean overall TTR | |||||||||||
| Full cohort | 49.9% (n=127) | 52.1% (n=1077) | 57.4% (n=7215) | 60.1% (n=29 753) | 59.4% (n=11 854) | 57.5% (n=5377) | 54.2% (n=1442) | 51.3% (n=203) | 42.4% (n=289) | 58.9% (n=57 337) | <0.001 |
| Heart failure | 46.2% (n=23) | 52.7% (n=139) | 55.1% (n=860) | 57.0% (n=4152) | 55.9% (n=2379) | 55.7% (n=1563) | 52.5% (n=523) | 47.9% (n=66) | 40.0% (n=127) | 55.8% (n=9832) | <0.001 |
| No heart failure | 50.7% (n=104) | 52.0% (n=938) | 57.4% (n=6355) | 60.1% (n=25 601) | 59.4% (n=9475) | 57.5% (n=3814) | 54.2% (n=919) | 51.3% (n=137) | 42.4% (n=162) | 59.6% (n=47 505) | <0.001 |
| Age<75 | 50.0% (n=127) | 52.0% (n=1059) | 57.3% (n=6828) | 59.8% (n=19 075) | 58.4% (n=5404) | 55.2% (n=1906) | 53.6% (n=576) | 50.6% (n=112) | 42.1% (n=219) | 58.4% (n=35 306) | <0.001 |
| Age≥75 | 0 | 59.4% (n=18) | 58.4% (n=387) | 60.6% (n=10 678) | 60.1% (n=6450) | 58.7% (n=3471) | 54.6% (n=866) | 52.3% (n=91) | 43.4% (n=70) | 59.8% (n=22 031) | <0.001 |
| % of patients with overall TTR≥60% | |||||||||||
| Full cohort | 29.9% (n=38) | 38.4% (n=413) | 50.1% (n=3613) | 54.8% (n=16 310) | 53.0% (n=6287) | 48.3% (n=2595) | 42.5% (n=613) | 38.4% (n=78) | 21.1% (n=61) | 24.4% (n=30 008) | <0.001 |
| Heart failure | 30.4% (n=7) | 36.7% (n=51) | 45.7% (n=393) | 48.6% (n=2018) | 45.1% (n=1072) | 44.5% (n=696) | 39.2% (n=205) | 30.3% (n=20) | 18.9% (n=24) | 45.6% (n=4486) | <0.001 |
| No heart failure | 29.8% (n=31) | 38.6% (n=362) | 50.7% (n=3220) | 55.8% (n=14 292) | 55.0% (n=5215) | 49.8% (n=1899) | 44.4% (n=408) | 42.3% (n=52) | 22.8% (n=37) | 53.7% (n=25 522) | <0.001 |
| Age<75 | 29.9% (n=38) | 38.1% (n=403) | 49.9% (n=3410) | 54.1% (n=10 322) | 51.5% (n=2781) | 43.8% (n=834) | 41.5% (n=239) | 39.3% (n=44) | 21.0% (n=46) | 51.3% (n=18 117) | <0.001 |
| Age≥75 | 0 | 55.6% (n=10) | 52.5% (n=203) | 56.1% (n=5988) | 54.4% (n=3506) | 50.7% (n=1761) | 43.2% (n=374) | 37.4% (n=34) | 21.4% (n=15) | 54.0% (n=11 891) | <0.001 |
INR, international normalised ratio.